Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S156100, C424S137100, C424S141100, C424S093700, C424S812000, C530S350000
Reexamination Certificate
active
07041634
ABSTRACT:
This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4. Also provided by this invention is a method of treating diabetes in a subject which comprises: a) containing viable insulin-producing cells, or tissue comprising such cells, within a device comprising a semipermeable membrane; b) transplanting an effective amount of such contained viable insulin-producing cells into the subject; and c) treating the subject with an effective amount of a substance which inhibits an immune-system costimulation event.
REFERENCES:
patent: 4663286 (1987-05-01), Tsang et al.
patent: 4673566 (1987-06-01), Goosen et al.
patent: 4696286 (1987-09-01), Cochrum
patent: 5334640 (1994-08-01), Desai et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 0613944 (1994-07-01), None
patent: 0613944 (1994-09-01), None
patent: WO9200092 (1992-01-01), None
patent: WO9300431 (1993-01-01), None
patent: WO9711607 (1997-04-01), None
Burgess et al. Journal of Cell Biology, 1990, 11 : 2129-2 138.
Lazar et al. Molecular and Cell Biology, 1988, 8: 1247-1252.
Tao. et al. The Journal of Immunology, 1989, 143(8): 2595-2601.
Gillies et al. Human Antibodies and Hybridomas, 1990, 1(1): 47-54.
Stites, DP et al, eds, 1997, Medical Immunology, Appleton & Lange, Stamford, Connecticut, p. 48).
Lenschow, DJ et al, 1992, Science, 257: 789-792.
Soon-shiong P et al, 1990, Horm Metab Res Suppl, 25: 215-9.
Akalin, E et al, 1996, Transplantation, 62(12): 1942-5.
Padrid PA et al, 1998, Am J Respir Cell Mol Biol, 1844): 453-62.
Stetlrer, W et al, 1995, J. Immunol, 155 (3): 1165-74.
Aomatsu, Y. et al. (1994) “Indefinite Graft Survival of Discordant Islet Xenografts in the NOD Mouse With Agarose Microencapsulation and 15-Deoxyspergualin”,Transplantation Proc.,26(2):805-06 (Exhibit 7).
Aomatsu, Y. et al., (1995) “Significance of Low Doses of 15-Deoxyspergualin in Agarose-Microencapsulated Discordant Islet Xenotransplantation”,Islet Xenotransplantation,292-93 (Exhibit 8).
Auchincloss, H., (1988) “Xenogeneic Transplantation”,Transplantation,46(1):1-20 (Exhibit 9).
Blazar, B.R., et al., (1993) “In Vivo Infusion of Soluble CTLA4-Ig Reduces Lethal Graft-Versus-Host Disease (GVHD) Induced Across the major Histocompatibility Complex (MHC) Barrier in Mice”,Blood,82(10):456a. 1809 (Exhibit 10).
de Vos, P. et al., (1994) “Possible Relationship Between Fibrotic Overgrowth of Alginate-Polysine-Alginate Microencapsualted Pancreatic Islets and the Microcapsule Integrity”,Transplantation Proc.,26(2):782-83 (Exhibit 11).
Forty, J. et al., (1992) “Hyperacute Rejection of Rabbit Hearts by Human Blood is Mediated by the Alternative Pathway of Complement”,Transplantation Proc.,24(2):488-89 (Exhibit 12).
Iwata, H. et al., (1992) “Marked Prolongation of Islet Xenograft Survival (Hamster to Mouse) by Microencapsulation and Administration of 15-Deoxyspergualin”,Transplantation Proc.,24(4):1517-18 (Exhibit 13).
Krych,M. et al., (1992) “complement receptors”,Current Opinion in Immunology,4(1): 8-13 (Exhibit 14).
Lacy, P., (1993) “Status of islet cell transplantation”,Diabetes Rev.,1(1):76-92 (Exhibit 15).
Lafferty, K. et al., (1988) “Circumventing rejection of islet grafts: an overview”, In: Van Schilfgaarde, R., and Hardy M. (eds.), Transplantation of the Endocrine Pancreas in Diabetes Medllitus. Elsevier Science Publishers B.V. (Biomedical Division), 279-91 (Exhibit 16).
Lanza, R. et al., (1995) “A Simple Method For Transplanting Discordant Islets Into Rats Using Alginate Gel Spheres”,Transplantation,59(10):1485-87 (Exhibit 17).
Lenschow, D. et al., (1992) “Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLAIg”,Science,257(5071):789-92 (Exhibit 18).
Mazaheri, R. et al., (1991) “Transplantation of Encapsulated Allogenic Islets Into Diabetic BB/W Rats: Effects of Immunosuppression”,Transplantation,51(4):750-54 (Exhibit 19).
Pearson, T.C. et al., (1994) “Transplantation Tolerance Induced by CTLA4-Ig”,Transplantation,57(12):1701-06 (Exhibit 20).
Platt, J. et al., (1991) “The Barrier to Xenotranplantation”,Transplantation,52(6):937-47 (Exhibit 21).
Platt, J. et al., (1991) “The Role of Natural Antibodies in the Activation of Xenogeneic Endothelial Cells”,Transplantation,52(6):1037-43 (Exhibit 22).
Rabinovitch, A. et al., (1990) “Cytotoxic Effects of Cytokines on Human Pancreatic Islet Cells in Monolayer Culture”,J. Clinical Endocrinology&Metabolism,71(1):152-56 (Exhibit 23).
Ricker, A. et al., (1986) “Hyperimmune Response to Microencapsulated Xenogeneic Tissue in Non Obese Diabetic Mice”,In: The Immunology of Diabetes Mellitus,Jaworski, M. (ed.) Elseview, Amsterdam, 193-200 (Exhibit 24).
Ricordi, C. et al., (1987) “Low-temperature culture of human islets ofin vivotreatment L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival”,Proc. Natl. Acad. Sci. USA,84:8080-84 (Exhibit 25).
Soon-Shiong, P. et al., (1992) “Successful Reversal of Spontaneous Diabetes in Dogs by Intraperitoneal Microencapsulated Islets”,Transplantation,54(5):769-74 (Exhibit 26).
Weber, C. et al., (1989) “Microencapsualted Dog and Rat Islet Xenografts Into Sterptozotocin-Diabetic and NOD Mice”,Hormone and Metabolic Res.,Supplement series 25:219-26 (Exhibit 27).
Weber, C. et al., (1990) “The Role of CD4+ Helper T Cells in the Destruction of Microencapsulated Islet Xenografts in NOD Mice”,Transplantation,49(2):396-404 (Exhibit 28).
Weber, C. et al., (1990) “Prolonged Functional Survival of Rat-to-NOD Mouse Islet Xenografts by Ultraviolet-B(UV-B) Irradiation Plus Microencapsulation of Donor islets”Transplantation Proc.,2391);764-66 (Exhibit 29).
Weber, C. et al., (1993) “Humoral Reaction to Microencapsulated Rat, Canine, and Porcine islet Xenografts in Spontaneously diabetic NOD Mice”,Transplantatin Proc.,25(1):462-63 (Exhibit 30).
Weber, C. et al., (1994) “NOD Mouse Peritoneal Cellular Response to Poly-L-Lysine-Alginate-Microencapsualted Rat Islets”,Transplantation Proc.26(3):1116-19 (Exhibit 31).
Dupuy, B., et al. (1991) “Microencapsulation of isolated pituitary cells by polyacrylamide microlatex coagulation on agarose beads”,Biomaterials,12 (5) : 493-496. (Exhibit 3).
Hakim, F.T., et al. (1995) “Acute Graft-Versus-Host Reaction can be Aborted by Blockade of Costimulatory Molecules”, J. Immunol., 155(4) :1757-1766. (Exhibit 4).
Steurer, W., et al. (1995) “Ex Vivo Coating of Islet Cell Allografts with Murine CTLA4/Fc Promotes Graft Tolerance”, J. Immunol., 155(3) : 1165-1174. (Exhibit 5).
Hagler Mary K.
Kapp Judith A.
Linsley Peter S.
Safley Susan A.
Weber Collin J.
Bristol Myers-Squibb Company
Cooper & Dunham LLP
Davis Minh-Tam
Emory University
Ungar Susan
LandOfFree
Method of inhibiting immune system destruction of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting immune system destruction of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting immune system destruction of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540413